Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Solanezumab versus placebo for progression of Alzheimer's disease
2008-007926-21Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) comparing Solanezumab with Placebo (2 arms). Primary endpoints: Change from baseline in ADAS-Cog11 and Change from baseline in ADCS-ADL. Started Mar 2009; status: completed.
02
Drugs
solanezumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2008-007926-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007926-21.